Two new treatment regimens for Helicobacter pylori eradication:: a randomised study

被引:46
作者
De Francesco, V
Zullo, A
Hassan, C
Faleo, D
Ierardi, E
Panella, C
Morini, S
机构
[1] Osped Nuovo Regina Margherita, I-00153 Rome, Italy
[2] Riuniti Hosp, Div Gastroenterol & Digest Endoscopy, Foggia, Italy
[3] Univ Foggia, Foggia, Italy
关键词
Helicobacter pylori;
D O I
10.1016/S1590-8658(01)80044-X
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Several studies have found a fairly low Helicobacter pylori eradication rate using a standard 7-day triple therapy in Italy. Recently, two new therapeutic schedules have been proposed with an eradication rate higher than 90%. This study compared the efficacy of these two treatment regimens. Patients and Methods. A total of 131 patients with Helicobacter pylori infection and either non-ulcer dyspepsia (73 patients) or peptic ulcer [58 patients] were enrolled. Helicobacter pylori infection was assessed by rapid urease test and histology on gastric biopsies. Patients were randomised to receive either a 5-day course of ranitidine bismuth citrate 400 mg bid, clarithromycin 500 bid, and tinidazole 500 bid, or a 10-day course of omeprazole 20 mg bid plus amoxycilin Ig bid for the first 5 days, and omeprazole 20 mg bid, clarithromycin 500 mg bid and tinidazole 500 mg bid for the remaining 5 days. Eradication: was assessed by endoscopy 4-6 weeks after therapy. Results. Overall, 4 patients (2 fop each treatment group) were lost to follow-up. Helicobacter pylori eradication rates were 67.2% (95% confidence interval: 55.7-78.7) and 65.2% (95% confidence interval. 53.7-76.6) at per protocol and intention-to-treat analyses, respectively, after the 5-day regimen, and 96.8% (95% confidence interval. 92.9-100) and 93.8% (95% confidence interval: BB-99.7) after the 10-day regimen (p <0.05). Both treatments were well tolerated, and no major side-effects were reported. Conclusions. The 5-day regimen gave disappointing results, while the eradication rate after the 10-day regimen was very high.
引用
收藏
页码:676 / 679
页数:4
相关论文
共 30 条
[1]  
Bazzoli F, 2000, GUT, V47, pA79
[2]  
Bigard MA, 1998, ALIMENT PHARM THER, V12, P383
[3]   HYPOTHESES ON THE PATHOGENESIS AND NATURAL-HISTORY OF HELICOBACTER-PYLORI INDUCED INFLAMMATION [J].
BLASER, MJ .
GASTROENTEROLOGY, 1992, 102 (02) :720-727
[4]  
Cammarota G, 2000, ALIMENT PHARM THERAP, V14, P73
[5]   Cervia Working Group Report:: Guidelines on the diagnosis and treatment of Helicobacter pylori infection [J].
Caselli, M ;
Parente, F ;
Palli, D ;
Covacci, A ;
Alvisi, V ;
Gasbarrini, G ;
Porro, GB .
DIGESTIVE AND LIVER DISEASE, 2001, 33 (01) :75-80
[6]  
Catalano F, 1998, ALIMENT PHARM THERAP, V12, P59
[7]   Relationship between antral lymphocyte density and basel gastrin levels in patients with Helicobacter pylori infection [J].
De Francesco, V ;
Zullo, A ;
Rinaldi, V ;
Hassan, C ;
Ballanti, P ;
Winn, S ;
Diana, F ;
Morini, S ;
Attili, AF .
DIGESTIVE AND LIVER DISEASE, 2000, 32 (08) :676-681
[8]   Re-treatment after Helicobacter pylori eradication failure [J].
Gisbert, JP ;
Boixeda, D ;
Bermejo, F ;
Rincón, MN ;
Higes, MJ ;
Arpa, MA ;
Arata, IG ;
de Argila, CM ;
Plaza, AG .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1999, 11 (09) :1049-1054
[9]  
Hamada H, 2000, ALIMENT PHARM THER, V14, P729
[10]  
Ierardi E, 1997, ITAL J GASTROENTEROL, V29, P470